Plant extracts and nutraceuticals are the most ancient and widespread form of medication employed by the general population. The pomegranate is a prehistoric, mystical and a highly differentiated fruit. Moreover, pomegranate is found in some medicinal systems as a cure for a variety of ailments. Pomegranate has been used for a long time for nutraceutical purposes. Current research indicates that the most medicinally useful pomegranate components include ellagitannins, anthocyanins, anthocyanidins, flavonoids, estrogenic flavonols and flavones. Also pomegranate seed oil contains 64-83% punicic acid. Therefore, this review focussed on the effects of punicic acid, particularly those that have been reported such as the anticarcinogenic, antioxidant, antiinflammatory and antidiabetic effects. As nutraceuticals appear to play a major role in the prophylaxis of various diseases, punicic acid could be an important and phytoconstituent among these agents. Nutraceuticals are generally regarded as safe to use with lower incidence of side effects. In spite of all these reports it is obvious that there is a clear need for more clinical studies.

Key words: Punicic acid, pomegranate seed oil, nutraceutical, therapeutic uses

Pomegranate seeds contain different components in addition to polyphenols, which may contribute to pomegranate’s useful effects[9]. Pomegranate seed oil (PSO) contains 12-20% of whole seed mass. Recently, PSO has received significant dietary attention. The oil’s possible useful effects have been attributed to its major bioactive constituent, PA, a conjugated linolenic acid (CLA), which constituted 64-83% of PSO[6-8]. Conjugated fatty acid (CFA) is the general term of positional and geometric isomers of polyunsaturated fatty acids with conjugated double bonds. It has been reported that CLA exhibited antiinflammatory, antiatherosclerotic, antiobesity, antitumor and antihypertensive effects[9-13].

Although the effects of PA on body have been well known, there is only little data about the metabolism of PA. Tsuzuki et al. reported that PA is quietly absorbed in rodent intestine. It has been shown that PA can be converted into cis 9, trans 11-18:2 in various

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
rat tissues, such as liver, adipose tissue, plasma and brain\cite{14,15}. Also, Yuan et al. have shown that PA can be incorporated into plasma and erythrocytes and a part of PA can also be metabolized into cis 9, trans 11-18:2 in humans. The mechanism of in vivo transformation of PA into cis 9, trans 11-18:2 is not precisely known\cite{16-20}.

Patel et al. suggested that oral application of pomegranate extract at levels up to 600 mg/kg/d did not produce any side effects in rats of either sex\cite{21}. In animal studies it has been reported that plasma levels of PA is increased adequately by dietary PA. No toxicity such as mutagenicity was observed in rats bred with PSO for 28 d (0 to 150 000 ppm, which resulted in a mean intake of 0 to 14 214 mg/kg/d). The level for no observable adverse effect was 4.3 g PSO/kg/d in rats\cite{22}. It was demonstrated that there was no adverse effect in patients treated with PSO capsules during 12 w in a prospective, placebo-controlled, randomized, double-blind trial in women with menopausal symptoms\cite{23}.

Recently, the number of reports on PA has increased. Actually, a new effect was reported by our group, PA exerted nitric oxide-mediated vasodilatory effect in aortic arteries of the rat\cite{24}. Therefore, in this review we mention about effects of PA, particularly antioxidant, antiinflammatory, antidiabetic and anticarcinogenic effects (fig. 1).

**Antioxidant and antiinflammatory effects of PA:**

It is well known that oxidative stress plays a considerable role in the pathogenesis of various diseases. There were many clinical and experimental studies on the antioxidant effect of PA. Schubert et al. have demonstrated that fermented pomegranate juice and PSO have antioxidant activity\cite{25}. Regarding the CLA compounds, Saha et al. reported that PA possessed hydroxyl radical scavenging activity, reducing properties and metal chelation particularly demonstrated by the trans isomer. Also, they reported that PA was a potent antioxidant agent, caused reduction in lipid peroxidation and scavenged free radicals in arsenic-induced toxicity\cite{26}.

Saha et al. suggested that PA has shown higher hypocholesterolemic and antiinflammatory activity due to high cis ingredients\cite{27}. Moreover, Bialonska et al. reported that urolithins, metabolites of PA, exhibited a significant antioxidant activity and growth of human gut bacteria\cite{28}. Also, in an experimental animal study, Binyamin et al. proposed that nano-drop formulation of PSO might be considered for the treatment of demyelinating diseases due to its antioxidant effect\cite{29}. It has been proposed that consumption of large amounts of CFA by the Asian and Middle East populations appears to be associated with the lower incidence of

![Fig. 1: Effects of punicic acid](image_url)
inflammatory diseases. Recent studies indicate that PA has a strong antiinflammatory effect through inhibition of tissue necrosis factor α (TNF-α)-induced elevation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and ameliorates colitis in an experimental rat model. Likewise, Bassaganya-Riera et al. provided in vivo molecular proof that PA ameliorated experimental inflammatory bowel disease by modulating T-cell and macrophage function through peroxisome proliferator activated receptors (PPAR-γ) and δ-dependent mechanisms. It was known that PPAR-γ and δ have potent inhibitor effects in intestinal inflammation in dextran sodium sulfate colitis. It was demonstrated that in interleukin-10 (IL-10) knockout mice PA ameliorated dextran sodium sulphate-induced inflammatory colitis and spontaneous panenteritis.

Necrotizing enterocolitis is the main reason of mortality and morbidity in infants and the aetiology is unknown. It was demonstrated that, administration of PA ameliorated intestinal injury in a rat necrotizing enterocolitis model. Also Caplan et al. demonstrated that PA reduced the rate of necrotizing enterocolitis and inflammatory intestinal diseases in the rat. Also in this model a recent study showed that PSO protected against necrotizing enterocolitis. It was suggested that this effect of PSO might be due to antiinflammatory effects and recovery of epithelial homeostasis by decreasing TNF-α, IL-6 and IL-8 levels. In addition they postulated that PA has considerable useful effects on integrity of gastrointestinal mucosa. In this study it was believed that PA is very important nutritional factor in the future. Also cold pressed PSO inhibited both cyclooxygenase and lipoxygenase enzymes in vitro.

PA AND DIABETES MELLITUS

Type 2 diabetes mellitus is related to defects in insulin release or lipid and glucose metabolisms. Prevention and treatment of diabetes are among the priority issues. Because of fruit extracts are safe, natural and readily available they have been used broadly in this manner. Also, there are a lot of traditional medicine that have been used for their useful effects in distinct diseases.

As mentioned above, CFAs are striking molecules because of their health benefits in various inflammatory diseases. Recent investigations suggest that oral administration of PSO to mice with dietary PSO improved insulin resistance and high-fat-diet-induced obesity. Vroegrijk et al. also showed that body weights were decreased by reducing fat mass in PSO fed animals during 12 w. But they did not find insulin concentration or a lower fasted glucose in these animals. Likewise, in another study Nekooeian et al. found that PSO ameliorated insulin secretion without changing fasting blood glucose in diabetic animals. Similarly, it was demonstrated that PA diminished fasting glucose levels and ameliorated glucose normalizing capability. Koba et al. found that PSO dose dependently decreased the perirenal adipose tissue weight at the end of 4 w of feeding with PSO. They also demonstrated that PA diminished hepatic triglyceride concentration and fatty tissue weights in mice, which may be partially related to an increase of fatty acid â-oxidation activity. But some reported data on the effect of PSO on lipid metabolism and concentration have been controversial. Contrary to what has been documented above, Nekooeian et al. found that PSO did not decrease blood glucose but enhanced insulin levels and this effect occurred despite any change in blood glucose levels. The mechanism of PSO-induced enhancement in insulin levels is not known. Also in that study it was shown that PSO did not alter lipid peroxidation but diminished the diabetes related oxidant stress. Finally, this study demonstrated that PSO ameliorated insulin secretion without altering fasting glucose levels. However, Yamasaki et al. demonstrated that administration of PSO (0.1 and 1.0% as PA) did not show significant effects on the epididymal and perirenal adipose tissue weight in male mice. It was found that 4 w treatment with PSO diminished cholesterol, high-density lipoprotein (HDL)-cholesterol ratio and triglyceride concentration compared to the placebo group in a placebo-controlled, double-blind, clinical trial. They also showed no beneficial correlation between PSO consumption and insulin profiles. Moreover, PSO was demonstrated to have an antioxidant activity and useful effects on lipid profile of dyslipidemic patients. Aroa et al. demonstrated that feeding of obese Otsuka Long-Evans Tokushima fatty (OLETTE) rats with dietary 1% PSO did not affect abdominal adipose tissue weights or blood lipid levels when compared to the normal diet group. But, hepatic triglyceride levels were diminished significantly. In contrast to this study, Aroa et al. suggested that, dietary PSO rich in 9c, 11t, 13c-CLA reduced hepatic triglyceride accumulation in hyperlipidemic OLET rats. In another study 1% dietary supplementation with PSO improved glucose tolerance and decreased inflammation in db/db mice. PA is reported to possess PPARγ agonist property. TNF-α mediated insulin resistance played a significant role in
the pathogenesis of diabetes mellitus and is associated with severe mitochondrial impairment. It was shown that PA improved glucose uptake, reactive oxygen species accumulation, mitochondrial biogenesis and energetics in TNF-α treated cell. In addition, treatment with PA was found to ameliorate TNF-α-induced alterations in proteins associated with mitochondrial dynamics like mitochondrial fission 1 protein and optic atrophy type 1. These findings suggest that PA can be considered as an active lead for the management of insulin resistance and associated mitochondrial dysfunctions. Furthermore, PA was shown to inhibit the expression of TNF-α and the activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and upregulate PPAR-α- and γ-responsive genes in the tissues containing glucose homeostasis in mice. Also in mice model it has been shown that PA activated PPARγ, enhanced PPARγ-responsive gene expression to ameliorate diabetes and inflammation activation. In a clinical trial, Asghari et al. suggested that treatment with PSO in dyslipidemic subjects did not affect serum TNF-α content.

In vitro studies reported by Anusree et al. found that PA upregulated glucose transporter type 4 (GLUT 4) expression and translocation in adipocytes enhanced adiponectin secretion. They suggested that PA is a potent nutraceutical agent and should be encouraged for use both as a therapeutic and prophylactic agent in diabetes mellitus.

Despite these controversial findings there are many evidences that PSO and PA could be useful in treatment of diabetes mellitus. Therefore, it would be of great interest to further investigate the pomegranate seed extracts for potential antidiabetic activity. However, to clarify beneficial effect of PA and its action mechanisms there is a need for further studies.

**PA AND CANCER**

There is an increase in the use of nutraceuticals in cancer treatment in last decade. Studies about use of PA in cancer are present. Anticancer effects of molecules present in pomegranate juice were investigated in early studies. Dickmen et al. showed the antiproliferative and apoptotic effects of pomegranate juice in breast cancer. There are different types of fatty acids such as long chain polyunsaturated fatty acids known to have potential anticancer activity. PA, a good example for this type of fatty acids, is under investigation for cancer treatment. In a study PA has inhibited breast cancer cell proliferation through its lipid peroxidation properties and also by affecting the protein kinase C pathway. Rocha et al. found that pomegranate ingredients including PA inhibit both proliferation of cell lines and secretion of proinflammatory cytokines.

PSO has been found to inhibit invasion and proliferation of different cell lines of human cancer. For example, the cytotoxic effects of pomegranate CLA on the MCF-7 mammary cancer cells together with an increased apoptosis of the MDA-MB-435 human breast cancer cells have been recently reported. The effect of PA on both oestrogen sensitive (MDA-ERa7) and insensitive breast cancer cell line (MDA-MB-231) was investigated by Grossmann et al. They found that PA inhibited MDA-ERa7 and MDA-MB-231 cell growth with a percentage of 96% and 92%, respectively, compared to control cells. Furthermore, PA produced apoptotic effect in both cell lines and impaired cellulary mitochondrial membrane potential. The breast cancer inhibitor features of PA are related to the protein kinase C pathway and lipid peroxidation.

Costantini et al. showed that PA remarkably inhibited cell viability in different breast cell lines (MCF-7 and MDA-MB-231) but not cancer cell lines of liver and colon. Toi et al. previously showed, PSO and fermented juice polyphenols to retard oxidation and prostaglandin synthesis, to inhibit breast cancer cell proliferation and invasion and to promote breast cancer cell apoptosis. They also firstly showed an antiangiogenic potential of pomegranate fractions. PA decreased tumour activity in mice skin cancer cells and played the role of a preventive agent by inhibiting ornithine decarboxylase enzyme, which is active in mouse skin cancer cell lines.

PA has also been studied in colon and prostate cancers. PA diminished incidence of chemically induced F344 rat colon carcinogenesis and expression of PPARγ in colon mucosa, not dose dependently. It is well known that prostate cancer is the second reason of cancer deaths in man. It is necessary to find less toxic but more effective therapeutic agents in the treatment of prostate cancer. Various oil acids including PA inhibit the expression of prostate specific antigen and steroid 5R-reductase type and dihydrotestosterone-induced androgen receptor nuclear accumulation. Also, they showed that PA stimulated DNA fragmentation and internal apoptotic activity through caspase-dependent pathway. Recently, there has been a renewed push to identify natural remedies such as pomegranate extract to fight prostate cancer. It was shown
that pomegranate extracts have pro-apoptotic and antiproliferative effects via stimulation of apoptosis and cell cycle arrest\cite{62,63}. A considerable amount of evidence has shown that pomegranate extracts could suppress the growth of human prostate cancer cell lines in vitro. Useful effect of pomegranate extracts on the entire different prostate cancer cell lines have been demonstrated in in vitro studies. Many studies showed that pomegranate extracts inhibit proliferation, invasion through Matrigel and induced apoptosis of LNCaP, PC3 and DU145 prostate cancer cells\cite{64}.

More recently, pomegranate extracts has been shown to inhibit testosterone and dihydrotestosterone levels in LNCaP and prostate cancer cell lines (22RV1)\cite{65}. Also, in vivo studies showed that pomegranate extracts inhibit prostate cancer development and progression, possibly via targeting inhibition of PI3K/Akt/mTOR signalling pathways in transgenic mouse model for prostate cancer\cite{66}. Also, PA may suppress prostate cancer cell invasion through blocking the arachidonic acid metabolism pathway in metastatic cell lines\cite{67}.

Anticarcinogenic properties of PSO could be related to its antiangiogenic activities and inhibition of prostaglandin synthesis. Also, dietary PSO was also shown to diminish growth of human prostate cancer LNCaP and DU 145 cells and to significantly reduce the invasiveness of the PC-3 cell line\cite{64}. Wang et al. have been suggested that pomegranate extracts including PA inhibit prostate cancer metastasis through targeting the CXCL12/CXCR4/AKT signalling axis\cite{68}. In recent years it has been demonstrated that combined administration of pomegranate extracts including luteolin, ellagic acid and PA have an increased anticancer activity. Anticancer activity of PA is mediated by decreasing cell migration and CXCL12 chemotaxis, increasing cell adhesion, inhibiting epithelial-mesenchymal transition and inhibiting angiogenesis and proliferation\cite{69}. In a 2 y phase II clinical trial on prostate cancer patients, pomegranate juice consumption normalized prostate specific antigen\cite{70}. More recently, another phase II clinical trial showed positive effects of PA in patients with prostate cancer\cite{71}.

Role of PA has also been investigated in metastatic prostate cancer. Pomegranate prevents metastasis by decreasing cell migration, increasing cell adhesion. But PA shows its antimetastatic activity in different mechanisms. Hyaluronan is mostly localized in the solid tumour’s stroma, stimulating tumour invasion, cell migration and metastasis\cite{72}. Antimetastatic effect of PA and pomegranate extract occurs via targeting hyaluronan signalling pathways in prostate cancer cells. Cytokines and chemokine’s can be mentioned among other possible mechanisms. PA inhibits this pathway and exhibits useful effects\cite{69,73}.

From the above documented information, it can be concluded that nutraceuticals have a significant role in the prevention of various ailments and PA in particular is an important constituent with great potential. These agents are safe to use and show low incidence of side effects. However, more clinical studies are necessary to realise their true potential.

**Acknowledgement:**

This study was supported by Akdeniz University, The Scientific Research Project Coordination Unit.

**Conflict of interest:**

The authors report no declarations of interest.

**Financial support and sponsorship:**

Nil.

**REFERENCES**

1. Graf BL, Raskin I, Cefalu WT, Ribnicky DM. Plant-derived therapeutics for the treatment of metabolic syndrome. Curr Opin Investig Drugs 2010;11:1107-15.
2. Eisenberg DM, Davis RB, Etter SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990-1997. Results of a follow-up National survey. JAMA 1998;280:1569-75.
3. Jurek J.A. Therapeutic applications of pomegranate (Punica granatum L.): A review. Altern Med Rev 2008;13:128-44.
4. Quideau S, Feldman KS. Ellagitannins chemistry. Chem Rev 1996;96:475-504.
5. Singh RP, Chidambaram Murthy KN, Jayaprakasha GK. Studies on the antioxidant activity of pomegranate (Punica granatum) peel and seed extracts using in vitro models. J Agric Food Chem 2002;50:81-6.
6. Kaufman M, Wiesman Z. Pomegranate oil analysis with emphasis on maldi-tof/ms triacylglycerol fingerprinting. J Agric Food Chem 2007;55:10405-13.
7. Lansky EP, Newman RA. Punica granatum (pomegranate) and its potential for prevention and treatment of inflammation and cancer. J Ethnopharmacol 2007;109:177-206.
8. Suzuki R, Noguchi R, Ota T, Abe M, Miyashita K, Kawada T. Cytotoxic effect of conjugated trienoic fatty acids on mouse tumor and human monocytic leukemia cells. Lipids 2001;36:477-82.
9. Lee KN, Kritechesky D, Pariza MW. Conjugated linoleic acid and atherosclerosis in rabbits. Atherosclerosis 1994;108:19-25.
10. Nicolosi RJ, Rogers EJ, Kritechesky D, Scimeca JA, Huth PJ. Dietary conjugated linoleic acid reduces plasma lipoproteins
and early aortic atherosclerosis in hypercholesterolemic hamsters. Artery 1997;22:266-77.

11. Park Y, Albright KJ, Liu W, Storkson JM, Cook ME, Pariza MW. Effect of conjugated linoleic acid on body composition in mice. Lipids 1997;32:853-8.

12. Park Y, Storkson JM, Albright KJ, Liu W, Pariza MW. Evidence that the trans-10,cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids 1999;34:235-41.

13. Park Y, Albright KJ, Storkson JM, Liu W, Cook ME, Pariza MW. Changes in body composition in mice during feeding and withdrawal of conjugated linoleic acid. Lipids 1999;34:243-8.

14. Yuan GF, Yuan JQ, Li D. Punicic acid from trichosanthes kirilowii seed oil is rapidly metabolized to conjugated linoleic acid in rats. J Med Food 2009;12:416-22.

15. Tsuzuki T, Kawakami Y, Abe R, Nakagawa K, Koba K, Imamura J, et al. Conjugated linolenic acid is slowly absorbed in rat intestine, but quickly converted to conjugated linoleic acid. J Nutr 2006;136:2153-9.

16. Nagata M, Hidaka M, Sekiya H, Kawano Y, Yamasaki K, Okumura M, et al. Effects of pomegranate juice on human cytochrome p450 2e9 and tolbutamide pharmacokinetics in rats. Drug Metab Dispos 2007;35:302-5.

17. Hidaka M, Okumura M, Fujita K, Ogikubo T, Yamasaki K, Iwakiri T, et al. Effects of pomegranate juice on human cytochrome p450 3a (cyp3a) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos 2005;33:644-8.

18. Yuan G, Sinclair AJ, Xu C, Li D. Incorporation and metabolism of punicic acid in healthy young humans. Mol Nutr Food Res 2009;53:1336-42.

19. El-Seedi HR, El-Said AM, Khalifa SA, Goransson U, Bohlin L, Borg-Karlson AK, et al. Biosynthesis, natural sources, dietary intake, pharmacokinetic properties and biological activities of hydroxycinnamic acids. J Agri Food Chem 2012;60:10877-95.

20. Boldbaatar D, El-Seedi HR, Findakly M, Babri S, Javan B, Choibash B, et al. Antigenotoxic and antioxidant effects of the mongolian medicinal plant Leptopyrum funarioides (l): An in vitro study. J Ethnopharmacol 2014;155:599-606.

21. Patel C, Dadhaniya P, Hingorani L, Soni MG. Safety assessment of pomegranate fruit extract: Acute and sub chronic toxicity studies. Food Chem Toxicol 2008;46:2728-35.

22. Meerts IA, Verspeek-Rip CM, Buskens CA, Keizer HG, Bassaganya-Riera J, Jouni ZE, et al. Toxicological evaluation of pomegranate seed oil. Food Chem Toxicol 2009;47:1085-92.

23. Auerbach L, Rakus J, Bauer C, Gerner C, Ullmann R, Wimmer H, et al. Pomegranate seed oil in women with menopausal symptoms: A prospective randomized, placebo-controlled, double-blinded trial. Menopause 2012;19:426-32.

24. Yilmaz U, Usta C, Tasatargil A, Ozdemir S. Pomegranate seed oil, a rich source of punicic acid, induces endothelium-dependent vasorelaxation in rat thoracic aortic rings. Atherosclerosis 2014;235:123-4.

25. Schubert SY, Lansky EP, Neeman I. Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids. J Ethnopharmacol 1999;66:11-17.

26. Saha SS, Ghosh M. Ameliorative role of conjugated linolenic acid isomers against oxidative DNA damage induced by sodium arsenite in rat model. Food Chem Toxicol 2010;48:3398-405.

27. Saha SS, Dasgupta P, Sengupta Bandyopadhyay S, Ghosh M. Synergistic effect of conjugated linolenic acid isomers against induced oxidative stress, inflammation and erythrocyte membrane disintegrity in rat model. Biochim Biophys Acta 2012;1820:1951-70.

28. Bialonska D, Kasiimsetty SG, Schrader KK, Ferreira D. The effect of pomegranate (Punica granatum L.) byproducts and ellagitannins on the growth of human gut bacteria. J Agric Food Chem 2009;57:8344-9.

29. Binyamin O, Larush L, Frid K, Keller G, Friedman-Levy Y, Ovadia H, et al. Treatment of a multiple sclerosis animal model by a novel nanodrop formulation of a natural antioxidant. Int J Nanomedicine 2015;10:7165-74.

30. Boussetta T, Raad H, Lettérón P, Gougerot-Pocidalo MA, Marie JC, et al. Punicic acid a conjugated linoleic acid inhibits TNF-a-induced neutrophil hyperactivation and protects from experimental colon inflammation in rats. PLoS One 2009;4:e6458.

31. Bassaganya-Riera J, DiGuardo M, Climent M, Vives C, Carbo A, Jouni ZE, et al. Activation of PPARδ and δ by dietary punicic acid ameliorates intestinal inflammation in mice. Br J Nutr 2011;106:878-86.

32. Nakajima A, Wada K, Katayama K, Sauberermann L, Osawa E, Nagase H, et al. Gene expression profile after peroxisome proliferator activator receptor-gamma ligand administration in dextran sodium sulfate mice. J Gastroenterol 2002;37:62-6.

33. Akisü M, Baka M, Coker I, Kültürsay N, Haseynov A. Effect of dietary N-3 fatty acids on hypoxia-induced necrotizing enterocolitis in young mice. N-3 fatty acids alter platelet-activating factor and leukotriene b4 production in the intestine. Biol Neonate 1998;74:31-8.

34. Caplan MS, Russell T, Xiao Y, Amer M, Kaup S, Jilling T. Effect of polyunsaturated fatty acid (PUFA) supplementation on intestinal inflammation and necrotizing enterocolitis (NEC) in a neonatal rat model. Pediatr Res 2001;49:647-52.

35. Coursodon-Boyiddle CF, Snarenberg CL, Adkins-Rieck CK, Bassaganya-Riera J, Hontecillas R, Lawrence P, et al. Pomegranate seed oil reduces intestinal damage in a rat model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 2012;303:G744-51.

36. Madkor HR, Mansour SW, Ramadan G. Modulatory effects of garlic, ginger, turmeric and their mixture on hyperglycaemia, dyslipidaemia and oxidative stress in streptozotocin-nicotinamide diabetic rats. Br J Nutr 2011;105:1210-7.

37. Banhani S, Swedan S, Alguraan Z. Pomegranate and type 2 diabetes. Nutr Res 2013;33:341-48.

38. Vroegrijk IO, van Diepen JA, van den Berg S, Westbroek I, Keizer H, Gambelli L, et al. Pomegranate seed oil, a rich source of punicic acid, prevents diet-induced obesity and insulin resistance in mice. Food Chem Toxicol 2011;49:1426-30.

39. McFarlin BK, Strohacker KA, Kueht ML. Pomegranate seed oil consumption during a period of high-fat feeding reduces weight gain and reduces type 2 diabetes risk in cd-1 mice. Br J Nutr 2009;102:54-9.

40. Nekoeoeian AA, Eftekhari MH, Adibi S, Rajaeifard A. Effects of pomegranate seed oil on insulin release in rats with type 2 diabetes. Iran J Med Sci 2014;39:130-5.

41. Hontecillas R, O'Shea M, Einerhand A, Diguardo M, Bassaganya-Riera J. Activation of PPAR gamma and alpha by punicic acid ameliorates glucose tolerance and suppresses obesity-related inflammation. J Am Coll Nutr 2009;28:184-95.

42. Koba K, Imamura J, Akashoshi A, Kohno-Murase J, Nishizono S, Iwabuchi M, et al. Genetically modified rapeseed oil containing cis-9,trans-11,cis-13-octadecatrienoic acid affects
body fat mass and lipid metabolism in mice. J Agric Food Chem 2007;55:3741-8.
43. Arao K, Wang YM, Inoue N, Hirata J, Cha JY, Nagao K, et al. Dietary effect of pomegranate seed oil rich in 9-cis, 11-trans, 13-cis conjugated linolenic acid on lipid metabolism in obese, hyperlipidemic OLETF rats. Lipids Health Dis 2004;3:24.
44. Yamasaki M, Kitagawa T, Koyanagi N, Chujo H, Maeda H, Kohno-Murase J, et al. Dietary effect of pomegranate seed oil on immune function and lipid metabolism in mice. Nutrition 2006;22:54-9.
45. Mirmiran P, Fazeli MR, Asghari G, Shafiee A, Azizi F. Effect of pomegranate seed oil on hyperlipidemic subjects: A double-blind placebo-controlled clinical trial. Br J Nutr 2010;104:402-6.
46. Anusree SS, Nisha VM, Priyanka A, Raghu KG. Insulin resistance by TNF-α is associated with mitochondrial dysfunction in 3T3-L1 adipocytes and is ameliorated by puninic acid, a PPARγ agonist. Mol Cell Endocrinol 2015;413:120-8.
47. Asghari G, Sheikholeslami S, Mirmiran P, Chary A, Hedayati M, Shafiee A, et al. Effect of pomegranate seed oil on serum TNF-α level in dyslipidemic patients. Int J Food Sci Nutr 2012;63:368-71.
48. Anusree SS, Priyanka A, Nisha VM, Das AA, Raghu KG. An in vitro study reveals the nutraceutical potential of puninic acid relevant to diabetes via enhanced glut4 expression and adiponectin secretion. Food Funct 2014;5:2590-601.
49. Dikmen M, Ozturk N, Ozturk Y. The antioxidiant potency of *Punica granatum* L. Fruit peel reduces cell proliferation and induces apoptosis on breast cancer. J Med Food 2011;14:1638-46.
50. Ozbay T, Nahta R. Delphinidin inhibits HER2 and ERK1/2 signaling and suppresses growth of Her2-overexpressing and triple negative breast cancer cell lines. Breast Cancer (Auckl) 2011;5:143-54.
51. Belury MA. Inhibition of carcinogenesis by conjugated linoleic acid: Potential mechanisms of action. J Nutr 2002;132:2995-8.
52. Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 1975;28:958-66.
53. Grossmann ME, Mizuno NK, Schuster T, Cleary MP. Puninic acid is an omega-5 fatty acid capable of inhibiting breast cancer proliferation. Int J Oncol 2010;36:421-6.
54. Rocha A, Wang L, Penichet M, Martins-Green M. Pomegranate juice and specific components inhibit cell and molecular processes critical for metastasis of breast cancer. Breast Cancer Res Treat 2012;136:647-58.
55. Kim ND, Mehta R, Yu W, Neeman I, Livney T, Amichay A, et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (*Punica granatum* L.) for human breast cancer. Breast Cancer Res Treat 2002;71:203-17.
56. Costantini S, Rusolo F, De Vito V, Moccia S, Picariello G, Capone F, et al. Potential antiinflammatory effects of the hydrophilic fraction of pomegranate (*Punica granatum* L.) seed oil on breast cancer cell lines. Molecules 2014;19:8644-60.
57. Toi M, Bando H, Ramachandran C, Melnick SJ, Imai A, Fife RS, et al. Preliminary studies on the antiangiogenic potential of pomegranate fractions in *vitro* and *in vivo*. Angiogenesis 2003;6:121-8.
58. HoraJJ, Maydew ER, Lansky EP, DwivediC. Chemopreventive effects of pomegranate seed oil on skin tumor development in cd1 mice. J Med Food 2003;6:157-61.
59. Kohno H, Suzuki R, Yasui Y, Hosokawa M, Miyashita K, Tanaka T. Pomegranate seed oil rich in conjugated linolenic acid suppresses chemically induced colon carcinogenesis in rats. Cancer Sci 2004;95:481-6.
60. Gasmi J, Sanderson JT. Growth inhibitory, antiandrogenic and pro-apoptotic effects of punic acid in LnCaP human prostate cancer cells. J Agric Food Chem 2010;58:12149-56.
61. Wang L, Martins-Green M. Pomegranate and its components as alternative treatment for prostate cancer. Int J Mol Sci 2014;15:14949-66.
62. Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, Mukhtar H. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 2005;102:14813-18.
63. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DI, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005;435:677-81.
64. Albrecht M, Jiang W, Kuni-Diaka J, Lansky EP, Gomersall LM, Patel A, et al. Pomegranate extracts potently suppress proliferation, xenograft growth and invasion of human prostate cancer cells. J Med Food 2004;7:274-83.
65. Ming DS, Pham S, Deb S, Chin MY, Kharmate G, Adomat H, et al. Pomegranate extracts impact the androgen biosynthesis pathways in prostate cancer models *in vitro* and *in vivo*. J Steroid Biochem Mol Biol 2014;143:19-28.
66. Adhami VM, Siddiqui IA, Syed DN, Lall RK, Mukhtar H. Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the tramp model. Carcinogenesis 2012;33:644-51.
67. Lansky EP, Jiang W, Mo H, Bravo L, Froom P, Yu W, et al. Possible synergistic prostatic cancer suppression by anatomically discrete pomegranate fractions. Invest New Drugs 2005;23:11-20.
68. Wang L, Li W, Lin M, Garcia M, Mulholland D, Lilly M, et al. Luteolin, ellagic acid and puninic acid are natural products that inhibit prostate cancer metastasis. Carcinogenesis 2014;35:2321-30.
69. Wang L, Ho J, Glackin C, Martins-Green M. Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis. Transl Oncol 2012;5:344-55.
70. Pantuck AJ, Leppert JT, Zomerodian N, Aronson W, Hong J, Barnard RJ, et al. Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res 2006;24:4018-26.
71. Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, et al. A randomized Phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer. Prostate Cancer Prostatic Dis 2013;16:50-5.
72. Turley EA. Hyaluronan and cell locomotion. Cancer Metastasis Rev 1992;11:21-30.
73. Wang L, Alcon A, Yuan H, Ho J, Li QJ, Martins-Green M. Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Integr Biol (Camb) 2011;3:742-54.